{"id":"doxorubicine-docetaxel-sequential","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"60-90","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"5-15","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"10-30","effect":"Peripheral neuropathy (docetaxel-related)"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. Docetaxel stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation. The sequential administration allows each agent to exert its mechanism independently, potentially improving efficacy and tolerability compared to concurrent dosing.","oneSentence":"A sequential chemotherapy regimen combining doxorubicin (an anthracycline topoisomerase II inhibitor) followed by docetaxel (a taxane microtubule stabilizer) to maximize cytotoxic effects against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:58.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (early-stage and metastatic)"},{"name":"Potentially other solid tumors in phase 3 evaluation"}]},"trialDetails":[{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT05474690","phase":"PHASE3","title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-11","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT00496795","phase":"PHASE2","title":"Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bergen","startDate":"2007-09","conditions":"Stage III Breast Cancer AJCC V7","enrollment":100},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT01049425","phase":"PHASE3","title":"Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2009-02-05","conditions":"Primary Breast Cancer, Her2 Non-overexpressing","enrollment":3198},{"nctId":"NCT03949634","phase":"PHASE3","title":"Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-09-01","conditions":"Early Breast Cancer","enrollment":272},{"nctId":"NCT00404066","phase":"PHASE2","title":"Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer","status":"COMPLETED","sponsor":"George Albert Fisher","startDate":"2006-10","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":21},{"nctId":"NCT03359694","phase":"PHASE3","title":"Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12","conditions":"Susceptibility, Genetic, Chemotherapy Effect","enrollment":300},{"nctId":"NCT03017404","phase":"NA","title":"A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2015-05","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT01660542","phase":"PHASE4","title":"An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-04","conditions":"Locally Advanced Breast Cancer","enrollment":96},{"nctId":"NCT00203502","phase":"PHASE2","title":"Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2005-09","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT01985841","phase":"PHASE2","title":"Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2011-10","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT00425516","phase":"PHASE2","title":"Breast Cancer Treated by Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2007-01","conditions":"Individualized Chemotherapy","enrollment":264},{"nctId":"NCT01985724","phase":"PHASE3","title":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2007-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT00010140","phase":"PHASE3","title":"Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer","status":"UNKNOWN","sponsor":"International Collaborative Cancer Group","startDate":"1997-08","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00005960","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"UNKNOWN","sponsor":"Amgen","startDate":"1999-10","conditions":"Pain, Prostate Cancer","enrollment":""},{"nctId":"NCT00054587","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2001-06","conditions":"Breast Cancer","enrollment":3010},{"nctId":"NCT00004906","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"1999-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00005908","phase":"PHASE2","title":"Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT00003953","phase":"PHASE2","title":"Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1999-02","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT00014352","phase":"PHASE2","title":"Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-09","conditions":"Prostate Cancer, Thromboembolism","enrollment":""},{"nctId":"NCT00005800","phase":"PHASE2","title":"Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"1999-04","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00149214","phase":"PHASE2","title":"Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-09","conditions":"Breast Cancer","enrollment":257},{"nctId":"NCT00270894","phase":"PHASE2","title":"Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2005-11","conditions":"Breast Neoplasm","enrollment":30},{"nctId":"NCT00721747","phase":"PHASE2","title":"Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer","status":"UNKNOWN","sponsor":"Grupo Oncológico Gallego","startDate":"2008-01","conditions":"Breast Cancer","enrollment":83},{"nctId":"NCT00174655","phase":"PHASE3","title":"BIG 02/98 Docetaxel - Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"1998-06","conditions":"Breast Neoplasms","enrollment":2887},{"nctId":"NCT00140075","phase":"PHASE3","title":"Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2000-11","conditions":"Adenocarcinoma","enrollment":606},{"nctId":"NCT00645866","phase":"PHASE2","title":"Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-04","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00314977","phase":"PHASE3","title":"Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2006-02","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT00033683","phase":"PHASE2","title":"Combination Chemotherapy in Treating Women With Resected Breast Cancer","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2001-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00793377","phase":"PHASE3","title":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"","conditions":"Primary Breast Cancer","enrollment":913},{"nctId":"NCT00212082","phase":"PHASE2","title":"Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2002-04","conditions":"Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT00431080","phase":"PHASE3","title":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-08","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT00525642","phase":"PHASE2, PHASE3","title":"Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2003-06","conditions":"Breast Neoplasms, Adjuvant, Chemotherapy","enrollment":603}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":189,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Doxorubicine + docetaxel sequential","genericName":"Doxorubicine + docetaxel sequential","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin and docetaxel are used in the treatment of breast cancer. Docetaxel is a small molecule tubulin stabilizer that works by stabilizing microtubules, which is a different mechanism than doxorubicin, which is classified as a stabilizer but its exact mechanism is not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}